Bruker (NASDAQ:BRKR) Lifted to Buy at Deutsche Bank

Deutsche Bank upgraded shares of Bruker (NASDAQ:BRKR) from a hold rating to a buy rating in a research report report published on Friday, April 12th, Benzinga reports. The firm currently has $50.00 price objective on the medical research company’s stock, up from their previous price objective of $40.00.

BRKR has been the subject of a number of other research reports. Zacks Investment Research cut shares of Bruker from a strong-buy rating to a hold rating in a research note on Monday, January 7th. BidaskClub cut shares of Bruker from a strong-buy rating to a buy rating in a research note on Thursday, April 4th. BTIG Research reiterated a buy rating and issued a $44.00 price target (up previously from $42.00) on shares of Bruker in a research note on Tuesday, February 12th. ValuEngine upgraded shares of Bruker from a hold rating to a buy rating in a research note on Tuesday, January 15th. Finally, Needham & Company LLC assumed coverage on shares of Bruker in a research note on Wednesday, January 2nd. They issued a strong-buy rating and a $39.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $41.63.

BRKR traded up $4.88 during trading hours on Friday, hitting $43.47. 2,243,315 shares of the company’s stock were exchanged, compared to its average volume of 726,591. Bruker has a 1-year low of $26.10 and a 1-year high of $44.47. The stock has a market capitalization of $6.82 billion, a price-to-earnings ratio of 31.05, a PEG ratio of 2.12 and a beta of 1.44. The company has a current ratio of 2.18, a quick ratio of 1.33 and a debt-to-equity ratio of 0.36.

Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, May 2nd. The medical research company reported $0.28 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.04. The business had revenue of $461.40 million during the quarter, compared to analysts’ expectations of $450.46 million. Bruker had a net margin of 9.48% and a return on equity of 26.36%. The firm’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.24 earnings per share. As a group, research analysts predict that Bruker will post 1.57 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in BRKR. JPMorgan Chase & Co. increased its holdings in Bruker by 33.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 96,033 shares of the medical research company’s stock valued at $3,213,000 after buying an additional 24,048 shares during the period. Bank of New York Mellon Corp increased its holdings in Bruker by 2.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 620,396 shares of the medical research company’s stock valued at $20,751,000 after buying an additional 15,838 shares during the period. Dimensional Fund Advisors LP increased its holdings in Bruker by 0.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 967,519 shares of the medical research company’s stock valued at $32,364,000 after buying an additional 6,388 shares during the period. Hsbc Holdings PLC increased its holdings in Bruker by 518.5% in the 3rd quarter. Hsbc Holdings PLC now owns 50,188 shares of the medical research company’s stock valued at $1,679,000 after buying an additional 42,074 shares during the period. Finally, GAM Holding AG bought a new position in Bruker in the 3rd quarter valued at about $211,000. 68.86% of the stock is currently owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

See Also: How to calculate compound interest

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.